The prevalence of the HPV 16 genome, integrated viral status and p53 genotype in cervical cancer population of north-eastern Hungary, the correlation with the established markers of tumour progression

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 113, Issue 1, 2004, Pages 83-86

  Hernádi, Zoltán ^a   Sápy, Tamás ^a   Krasznai, Zoárd T ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Cervical cancer; Correlation with tumour progression; HPV 16 integration; P53 Genotype; Prevalence in Hungary

Indexed keywords

BIOCHEMICAL MARKER; PROTEIN P53; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DETERMINATION; EVALUATION; FEMALE; GENOME ANALYSIS; GENOTYPE; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; HUNGARY; HYBRIDIZATION; LYMPH NODE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SOUTHERN BLOTTING; TUMOR GROWTH; UTERINE CERVIX CANCER; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; WART VIRUS;

EID: 1442311002     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2003.05.001     Document Type: Article

References (19)

1. Fisher S.G. Epidemiology: a tool for the study of human papillomavirus-related carcinogenesis. Intervirology. 37:1995;215-225.
2. Zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim. Biophys. Acta. 1288:1996;F55-F78.
3. Daniel B., Mukherjee G., Seshadri L., Vallikad E., Krishna S. Changes in the physical state and expression of human papillomavirus type 16 in the progression of cervical intraepithelial neoplasia lesions analysed by PCR. J. Gen. Virol. 76:1995;2589-2593.
4. Matsukura T., Koi S., Sugase M. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology. 172:1989;63-72.
5. Das B.C., Sharma J.K., Gopalakrishna V., Luthra U.K. Analysis by polymerase chain reaction of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic and neoplastic lesions. J. Gen. Virol. 73:1992;2327-2336.
6. Pirami L., Giache V., Becciolini A. Analysis of HPV 16, 18, 31 and 35 DNA in pre-invasive and invasive lesions of the uterine cervix. J. Clin. Pathol. 50:1997;600-604.
7. Unger E.R., Vernon S.D., Thoms W.W.et al. Human papillomavirus and disease-free survival in FIGO stage Ib cervical cancer. J. Infect. Dis. 172:1995;1184-1190.
8. Vernon S.D., Unger E., Miller D.L., Lee D.R., Reeves W.C. Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer. Int. J. Cancer. 74:1997;50-56.
9. Storey A., Thomas M., Kalita A.et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 393:1998;229-234.
10. Rosenthal A.M., Ryan A., Rajai M.A.-J., Storey A., Harwood C., Jacobs J.J. p53 codon 72 polymorhism and risk of cervical cancer in UK. Lancet. 352:1998;871-975.
11. Minaguchi T., Kanamori Y., Matsushima M., Yoshikawa H., Taketani Y., Nakamura Y. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/ 18 infections. Cancer Res. 58:1998;4585-4586.
12. Szarka K., Veress G., Kónya J., Gergely L. Frequency of p53 codon 72 genotypes in human papillomavirus associated squamous intraepithelial lesions and cervical cancer. Anticancer Res. 19:1999;2377-2380.
13. Evander M., Boden E., Bjersing L., Rylander E., Wadell G. Oligonucleotide primers for DNA amplification of the early regions 1, 6 and 7 from human papillomavirus types 6, 11, 16, 18, 31 and 33. Arch. Virol. 116:1991;221-233.
14. Szarka K., Veress G., Juhász A.et al. Integration status of virus DNA and p53 codon 72 polymorphism in human papillomavirus type 16 positive cervical cancers. Anticancer Res. 20:2000;2161-2168.
15. Berumen J., Casas L., Segura E., Amezcua J.L., Garcia-Carranca A. Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to the retention of E1/E2 genes. Int. J. Cancer. 56:1994;640-645.
16. Jeon S., Allen-Hoffman B.L., Lambert P.F. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69:1995;2989-2997.
17. Berumen J., Unger E.R., Casas L., Figuerua P. Amplification of human papillomavirus types 16 and 18 in invasive cervical cancer. Hum. Pathol. 26:1995;676-681.
18. Nishikawa A., Fujimoto T., Akutagawa N., Iwasaki M., Takeuchi M., Fujinaga K., Kudo R. p53 polymorphism (codon-72) has no correlation with the development and the clinical features of cervical cancer. Int. J. Gynecol. Cancer. 10:2000;402-407.
19. Ngan H.Y.S., Liu V.W.-S., Liu S.S., Cheng D.K.-L., Ng T.-Y., Wong L.-C. Homozygous arginine at codon 72 of p53 has no prognostic significance in cervical cancer. Tumor Biol. 21:2000;135-138.